SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

Drug Requested: Zynteglo® (betibeglogene autotemcel) **(J3393) (Medical)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

A. Quantity Limit (max daily dose) [NDC Unit]:

- Zynteglo up to 4 infusion bags, 20 mL/infusion bag, overwrap, and metal cassette: 73554-3111-xx
- A single dose of Zynteglo containing a minimum of 5.0×10^6 CD34+ cells/kg of body weight, in one or more infusion bags

B. Max Units (per dose and over time) [HCPCS Unit]:

- A single dose of Zynteglo containing a minimum of 5.0×10^6 CD34+ cells/kg of body weight, in one or more infusion bags

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Authorization Criteria: Coverage will be provided for one treatment course (1 dose of Zynteglo) and may not be renewed.

- ❑ Member 4 years of age or older
- ❑ Provider has considered use of prophylaxis therapy for seizures prior to initiating myeloablative conditioning
- ❑ Member has been screened for hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus 1 and 2 (HTLV-1/HTLV-2), and human immunodeficiency virus (HIV) in accordance with clinical guidelines prior to collection of cells (leukapheresis)
- ❑ Member does not have a history of hypersensitivity to dimethyl sulfoxide (DMSO)
- ❑ Member has not used prophylactic HIV anti-retroviral medication or hydroxyurea within 30 days prior to mobilization (or for the expected duration for elimination of those medications) and until all cycles of apheresis are completed (Note: if a member requires anti-retrovirals for HIV prophylaxis, confirm a negative test for HIV before beginning mobilization and apheresis)
- ❑ Iron chelation therapy has been discontinued for at least 7 days prior to initiating myeloablative conditioning therapy and myelosuppressive iron chelators will be avoided for 6 months posttreatment
- ❑ Member has not received other gene therapies (e.g., Casgevy [exagamglogene autotemcel], etc.)**
- ❑ Member will receive periodic life-long monitoring for hematological malignancies
- ❑ Member is eligible to undergo hematopoietic stem cell transplant (HSCT) and has not had prior HSCT
- ❑ Member does not have a known and available human leukocyte antigen (HLA) matched family donor willing to participate in an allogeneic HSCT
- ❑ Member has a documented diagnosis of beta thalassemia (excludes alpha-thalassemia and hemoglobin S/ß-thalassemia variants) as outlined by the following:
  - ❑ Member diagnosis is confirmed by HBB sequence gene analysis showing biallelic pathogenic variants
  - ❑ Member has severe microcytic hypochromic anemia, absence of iron deficiency, anisopoikilocytosis with nucleated red blood cells on peripheral blood smear, and hemoglobin analysis that reveals decreased amounts or complete absence of hemoglobin A (HbA) and increased HbA2 with or without increased amounts of hemoglobin F (HbF)
- ❑ Member has transfusion-dependent disease defined as a history of transfusions of at least 100 mL/kg/year of packed red blood cells (pRBCs) or with 8 or more transfusions of pRBCs per year in the 2 years preceding therapy
- ❑ Member will be maintained at a Hb ≥ 11 g/dL for 30 days prior to mobilization and 30 days prior to myeloablative conditioning

(Continued on next page)

- ❑ Member does not have any of the following:
  - ❑ Severely elevated iron in the heart (i.e., members with cardiac T2* less than 10 msec by magnetic resonance imaging [MRI])
  - ❑ Advanced liver disease (i.e., persistent AST, ALT, or direct bilirubin value > 3 times the upper limit of normal (ULN), baseline prothrombin time or partial thromboplastin time > 1.5 times the ULN, MRI of the liver demonstrated cirrhosis, or liver biopsy demonstrated bridging fibrosis, active hepatitis, or cirrhosis)
  - ❑ Members with an MRI of the liver with results demonstrating liver iron content ≥ 15 mg/g (unless biopsy confirms absence of advanced disease)

** Requests for subsequent use of betibeglogene after receipt of other gene therapies (e.g., exagamglogene, etc.) will be evaluated on a case-by-case basis

Medication being provided by: Please check applicable box below

- ❑ **Location/site of drug administration:** _____

  NPI or DEA # of administering location: _____

  OR

- ❑ **Specialty Pharmacy – PropriumRx**

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

***Approved by Pharmacy and Therapeutics Committee**: ~~11/18/2022;~~ **9/26/2024**
REVISED/UPDATED/REFORMATTED: ~~11/29/2022; 10/15/2024, 4/10/2025; 4/25/2025~~**; 9/24/2026**